Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY 4.0Frontiers in Oncology

Lipid metabolism mediating oxaliplatin resistance in colorectal cancer

  • Siqi Han1
  • Liqiang Gu2
  • Ziyu Ren1
  • Jingxian Hu1
  • Ying Zhao1
  • Zhenying Zhao3
  • Yijia Wang4
4 affiliations
  1. 1Graduate School of Tianjin University of Traditional Chinese Medicine
  2. 2Department of Colorectal Surgery, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University
  3. 3Department of Pharmacy, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University
  4. 4Department of Pathology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University
Read full textPDFDOICite

Abstract

Introduction: As a core drug in chemotherapy regimens for colorectal cancer, the clinical efficacy of oxaliplatin is compromised by multiple resistance mechanisms. Lipid metabolism, a crucial component of metabolic pathways, is known to affect the efficacy of various chemotherapeutic agents. However, to the best of our knowledge, the role of lipid metabolism in oxaliplatin resistance remains unreviewed.

Areas covered: In this review, we analyze the relationship between lipid metabolism and oxaliplatin efficacy from the perspectives of DNA damage, ferroptosis, ROS accumulation, cellular dormancy, antitumor immunity, vascular remodeling, and autophagy. This review covers nearly all known oxaliplatin resistance factors, summarizing the regulatory role of lipid metabolism across both basic and clinical studies. Given that clinical studies remain relatively scarce compared to basic research, the impact of factors directly regulated by lipid metabolism on clinical outcomes is analyzed. Based on this, their relationship with oxaliplatin efficacy is inferred, and potential directions for future clinical research are highlighted.

Expert opinion/commentary: By summarizing the relationship between lipid metabolism and oxaliplatin resistance, this review provides an important theoretical basis for improving chemotherapy efficacy in colorectal cancer and developing novel combination therapies based on metabolic interventions.

Related

  1. IRF4 transcriptionally activates CD36 to regulate glycolysis and suppress oxaliplatin resistance in colorectal cancer
    Qing Sun, Dongliang Zhao, Zhongcai Yao +2
    The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of PharmacologyPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  2. Exogenous carnitine can modulate oxaliplatin sensitivity in colorectal cancer cells in vitro
    Yufang Fan, Jian Huang, Liqiang Dai +8
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0OncologyCrossref
  3. Ellagic acid promoted efficacy of oxaliplatin on wild-type TP53 colorectal cancer via regulating ataxia-telangiectasia mutated protein kinase and Wip1
    Ying Zhao, Mingqian Ma, Siqi Han +7
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefEurope PMCEurope PMCPMC
  4. Synergistic induction of pyroptosis-like cell death in colorectal cancer cells by norcantharidin and low-dose oxaliplatin promotes M1 macrophage polarization
    Jia Lang, XueLian Zhu, Qian Chen +3
    BMC CancerPeer-reviewedCC BY-NC-ND 4.0Full textOncologyPMC
  5. Integrated Transcriptomic Analysis Identifies ENO3 as a Candidate Lactate Metabolism‐Associated Biomarker in Colorectal Cancer Metastasis
    Jiahao Qian, Miaomiao Wang, Jiaqi Liu +1
    Cancer reports (Hoboken, N.J.)Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{han2026lipid,
  title = {{Lipid metabolism mediating oxaliplatin resistance in colorectal cancer}},
  author = {Siqi Han and Liqiang Gu and Ziyu Ren and Jingxian Hu and Ying Zhao and Zhenying Zhao and Yijia Wang},
  journal = {Frontiers in Oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1976409},
  url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1976409/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Lipid metabolism mediating oxaliplatin resistance in colorectal cancer
AU  - Siqi Han
AU  - Liqiang Gu
AU  - Ziyu Ren
AU  - Jingxian Hu
AU  - Ying Zhao
AU  - Zhenying Zhao
AU  - Yijia Wang
PY  - 2026
DA  - 2026/10/22
JO  - Frontiers in Oncology
DO  - 10.3389/fonc.2026.1976409
UR  - https://www.frontiersin.org/articles/10.3389/fonc.2026.1976409/full
AB  - Introduction: As a core drug in chemotherapy regimens for colorectal cancer, the clinical efficacy of oxaliplatin is compromised by multiple resistance mechanisms. Lipid metabolism, a crucial component of metabolic pathways, is known to affect the efficacy of various chemotherapeutic agents. However, to the best of our knowledge, the role of lipid metabolism in oxaliplatin resistance remains unreviewed.  Areas covered: In this review, we analyze the relationship between lipid metabolism and oxaliplatin efficacy from the perspectives of DNA damage, ferroptosis, ROS accumulation, cellular dormancy, antitumor immunity, vascular remodeling, and autophagy. This review covers nearly all known oxaliplatin resistance factors, summarizing the regulatory role of lipid metabolism across both basic and clinical studies. Given that clinical studies remain relatively scarce compared to basic research, the impact of factors directly regulated by lipid metabolism on clinical outcomes is analyzed. Based on this, their relationship with oxaliplatin efficacy is inferred, and potential directions for future clinical research are highlighted.  Expert opinion/commentary: By summarizing the relationship between lipid metabolism and oxaliplatin resistance, this review provides an important theoretical basis for improving chemotherapy efficacy in colorectal cancer and developing novel combination therapies based on metabolic interventions.
SN  - 2234-943X
ER  -